UK-based T-Cypher Bio Ltd has appointed Thomas Lars Andresen as chief executive officer effective 1 August, to lead the company’s T cell receptor therapy programmes. Dr Andresen has more than 20 years of experience in biomaterial and biological engineering for drug delivery, immune modulation and cell therapy. He has founded several clinical stage immunotherapy companies including Torque Therapeutics Inc in the US and MonTa Biosciences ApS in Denmark.
T-Cypher Bio announced the appointment on 15 July 2021.
Copyright 2021 Evernow Publishing Ltd